FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014160513> ?p ?o ?g. }

• W2014160513 endingPage "414" @default.
• W2014160513 startingPage "401" @default.
• W2014160513 abstract "Colorectal cancer is the most commonly diagnosed cancer in the EU. Various randomised studies have shown a survival benefit with chemotherapy in the adjuvant setting. Adjuvant chemotherapy with 5-fluorouracil/folinic acid (5FU/FA) for 6 months after curatively resected node-positive colon cancer has become the standard practice. However, controversy still exists regarding the optimal regimen and whether to treat node-negative patients. The latest QUASAR trial results seem to strengthen the argument in favour of adjuvant treatment of Dukes B cancer. Patients with Dukes B tumours and any adverse prognostic indicator should be given the benefit of adjuvant therapy. A number of novel agents (oxaliplatin, irinotecan) showing activity in advanced disease are currently being evaluated in the adjuvant setting. A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago. 5FU/FA has been the mainstay of therapy for metastatic colorectal cancer for over 40 years and confers a survival benefit over supportive care. The response rate of 5FU is improved by modulation with FA or by continuous infusional regimens (currently the best expected response rate is around 20-25%). As per the recent National Institute for Clinical Excellence guidelines, the oral agents capecitabine or tegafur with uracil (in combination with FA) can be used as first-line treatment in metastatic colorectal cancer and, although their response rate has not been directly compared to infusional 5FU, survival is unlikely to be inferior. Newer chemotherapeutic agents like irinotecan and oxaliplatin are now entering regular usage due to improved response rates (around 50% in 5FU/FA-containing doublets) and survival. Irinotecan monotherapy is second-line treatment approved by the National Institute for Clinical Excellence, although sequential infusional 5FU/FA irinotecan to infusional 5FU/FA oxaliplatin may convey the best survival with the least side effects. The position of combination chemotherapy before (to downstage) or after metastasectomy (usually from the liver) is still a topic of heated debate. Other routes (intrahepatic, intraperitoneal) are still to be proven and not recommendable outside the trial setting. The latest results of chemotherapy combinations with biological treatments (bevacuzimab and cetuximab) have been very promising indeed. Further improvements in survival, response and quality of life are expected. ." @default.
• W2014160513 created "2016-06-24" @default.
• W2014160513 creator A5022762743 @default.
• W2014160513 creator A5060816944 @default.
• W2014160513 date "2005-01-01" @default.
• W2014160513 modified "2023-10-01" @default.
• W2014160513 title "Chemotherapy for Colorectal Cancer" @default.
• W2014160513 cites W141482010 @default.
• W2014160513 cites W1845706120 @default.
• W2014160513 cites W1886850372 @default.
• W2014160513 cites W1902766545 @default.
• W2014160513 cites W1918813770 @default.
• W2014160513 cites W1923257668 @default.
• W2014160513 cites W1935492807 @default.
• W2014160513 cites W1941365207 @default.
• W2014160513 cites W1958418663 @default.
• W2014160513 cites W1962875322 @default.
• W2014160513 cites W1976067359 @default.
• W2014160513 cites W1978779682 @default.
• W2014160513 cites W1980873666 @default.
• W2014160513 cites W1990105318 @default.
• W2014160513 cites W1997008356 @default.
• W2014160513 cites W2000749137 @default.
• W2014160513 cites W2005496035 @default.
• W2014160513 cites W2006824814 @default.
• W2014160513 cites W2008398178 @default.
• W2014160513 cites W2012852444 @default.
• W2014160513 cites W2016791396 @default.
• W2014160513 cites W2029762964 @default.
• W2014160513 cites W2032146688 @default.
• W2014160513 cites W2032541464 @default.
• W2014160513 cites W2033465919 @default.
• W2014160513 cites W2051686420 @default.
• W2014160513 cites W2059234543 @default.
• W2014160513 cites W2067482493 @default.
• W2014160513 cites W2069703793 @default.
• W2014160513 cites W2070573248 @default.
• W2014160513 cites W2073846703 @default.
• W2014160513 cites W2093871448 @default.
• W2014160513 cites W2096122707 @default.
• W2014160513 cites W2099039431 @default.
• W2014160513 cites W2112656316 @default.
• W2014160513 cites W2121368761 @default.
• W2014160513 cites W2121543823 @default.
• W2014160513 cites W2127558096 @default.
• W2014160513 cites W2128403792 @default.
• W2014160513 cites W2128447158 @default.
• W2014160513 cites W2133399075 @default.
• W2014160513 cites W2138926750 @default.
• W2014160513 cites W2139393303 @default.
• W2014160513 cites W2139730244 @default.
• W2014160513 cites W2140822728 @default.
• W2014160513 cites W2141768150 @default.
• W2014160513 cites W2145224595 @default.
• W2014160513 cites W2157769714 @default.
• W2014160513 cites W2159848047 @default.
• W2014160513 cites W2162313061 @default.
• W2014160513 cites W2164621617 @default.
• W2014160513 cites W2165070253 @default.
• W2014160513 cites W2166127437 @default.
• W2014160513 cites W2171232394 @default.
• W2014160513 cites W2171680834 @default.
• W2014160513 cites W2217081518 @default.
• W2014160513 cites W2252383071 @default.
• W2014160513 cites W2255487108 @default.
• W2014160513 cites W2264089739 @default.
• W2014160513 cites W2314927739 @default.
• W2014160513 cites W2315913422 @default.
• W2014160513 cites W2418999255 @default.
• W2014160513 cites W2469345929 @default.
• W2014160513 cites W2602544133 @default.
• W2014160513 cites W4243221014 @default.
• W2014160513 cites W4248316544 @default.
• W2014160513 cites W4248476792 @default.
• W2014160513 cites W4250091029 @default.
• W2014160513 doi "https://doi.org/10.1159/000091441" @default.
• W2014160513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16479107" @default.
• W2014160513 hasPublicationYear "2005" @default.
• W2014160513 type Work @default.
• W2014160513 sameAs 2014160513 @default.
• W2014160513 citedByCount "48" @default.
• W2014160513 countsByYear W20141605132012 @default.
• W2014160513 countsByYear W20141605132013 @default.
• W2014160513 countsByYear W20141605132014 @default.
• W2014160513 countsByYear W20141605132015 @default.
• W2014160513 countsByYear W20141605132016 @default.
• W2014160513 countsByYear W20141605132017 @default.
• W2014160513 countsByYear W20141605132018 @default.
• W2014160513 countsByYear W20141605132019 @default.
• W2014160513 countsByYear W20141605132020 @default.
• W2014160513 countsByYear W20141605132021 @default.
• W2014160513 countsByYear W20141605132022 @default.
• W2014160513 countsByYear W20141605132023 @default.
• W2014160513 crossrefType "journal-article" @default.
• W2014160513 hasAuthorship W2014160513A5022762743 @default.
• W2014160513 hasAuthorship W2014160513A5060816944 @default.
• W2014160513 hasConcept C121608353 @default.
• W2014160513 hasConcept C126322002 @default.

• next